Used in research and development for Alzheimer’s disease, this antibody targets amyloid-beta peptides in the brain, aiming to reduce plaque buildup associated with disease progression. It is employed in preclinical studies to evaluate efficacy, pharmacokinetics, and binding specificity. Due to its high selectivity for soluble and aggregated forms of amyloid-beta, it serves as a reference standard in immunoassays and histopathological analysis. It is also utilized in comparative studies with other anti-amyloid therapies to support therapeutic antibody development.